Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Prior to joining Alembic, Krishnan served as Vice President and CFO at Syngene Scientific Solutions, a subsidiary of Syngene International, since May 2020. During his tenure, he played a crucial role in driving strategy, business finance, mergers & acquisitions, governance and risk management. He has also held key leadership positions at Vodafone and Tata Trusts.
Krishnan brings with him expertise in business finance, M&A, scalable systems implementation, and governance frameworks, along with managing diverse finance teams.
Meanwhile, the company also informed that R. K. Baheti, Director – Finance and the current CFO, has relinquished his role as CFO effective 7 July 2025. However, he will continue to serve on the board as an executive director, in line with the terms of his appointment.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.
The company’s consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.
The scrip rose 0.37% to Rs 1,004.20 on the BSE.
Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI).
-“Pivya” is an FDA approved product to treat uncomplicated UTIs in the US market.
-“MEC” is a product in development for treatment of the complicated UTIs in the US market.
As a product development company they have minimal turnover in last 3 years.
Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). The first product ‘Pivya’ is an FDA approved product to treat uncomplicated UTIs in the US market. The second product ‘MEC’ is in development for the treatment of complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years. Alembic Pharma stated that the acquisition has been made to market the US FDA approved product and under-development product owned by the Utility in USA.
The acquisition cost involves a cash component plus profit share out of future profits. The total amount payable is approximately $12 million. The payout would happen in staggered manner over period of time, depending on milestones achieved.
The scrip advanced 0.95% to currently trade at Rs 999.05 on the BSE.